Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
ABBOTINDIA
Ms. Maithilee Mistry · Mumbai, India · 3,679 employees
₹27,745.00
▼-0.57%ABBOTINDIA is trading near its 52-week low despite strong fundamentals, suggesting potential undervaluation in the specialty pharmaceutical sector.
Exchange
NSI
Currency
INR
Day range
₹27,600.00 – ₹28,090.00
52-week range
₹25,150.00 – ₹35,310.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis85% confidence
The stock appears undervalued relative to its 52-week range and strong fundamentals, trading significantly below its 52-week high with an attractive P/E for its growth profile.
21.4% below the 1-year high · trend down
Hedge-fund memo
Today
Stock is down slightly (-0.57%) but trading within a narrow range near the lower end of its 52-week range.
This week
No specific weekly movement data provided, but the stock is near its 52-week low.
This month
No specific monthly movement data provided, but the stock is near its 52-week low.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
1 headlines · 1 outlets · 7d
TradingView·4d ago·neutral headline
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 0 of 3 recent quarters (EPS actual vs. consensus).
185.85 vs 186.7
-0.46% surprise
176.92 vs 181.55
-2.55% surprise
172.17 vs 191.3
-10.00% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| ABBOTINDIA | 589.56B | 37.95 | 34.46% | 27.02% | 6.50% |
| SANOFI | 78.76B | 25.42 | — | 28.33% | -11.90% |
| ALKEM | 678.23B | 29.43 | 17.56% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory changes in the pharmaceutical industry
Mitigation: Diversified product portfolio reduces dependency on any single regulatory decision
Increased competition from generic drug manufacturers
Mitigation: Strong brand recognition and specialty products provide competitive advantage
Business intelligence
Competitive moat
Strong brand recognition, established distribution network, and diverse portfolio of branded generic formulations provide a durable competitive advantage in the Indian pharmaceutical market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Potential new product launches in specialty segments
Expansion in rural healthcare markets
Thesis builder
Bull case
Strong brand recognition, diverse product portfolio, and efficient operations position ABBOTINDIA for continued growth in India's expanding healthcare market.
Base case
The company maintains steady growth with moderate revenue growth of 6.50% YoY and consistent profitability.
Bear case
Increased competition and potential regulatory headwinds could pressure margins and growth.
Time horizon
Long-term (3-5 years)
Est. CAGR
8-12%
Entry (qual.)
Current levels near 52-week low provide an attractive entry point for investors with a long-term perspective.
Exit (qual.)
Consider trimming positions if the stock approaches its 52-week high of 35,310 INR without fundamental justification.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how ABBOTINDIA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain ABBOTINDIA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Given the strong fundamentals and current price position, the stock presents an attractive entry point for long-term investors.
Annual income statement, oldest → newest. Live via Yahoo.
| 11.42% |
| 14.60% |
| LALPATHLAB | 314.34B | 58.26 | — | 25.46% | 19.10% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹27,600.00
Resistance (day/52w high)
₹28,090.00
Volume
9,930
Trend
down
RSI (14)
64
MACD
bearish
MA cross
death
50-day MA
₹26,803.40
200-day MA
₹27,364.35
vs 200-DMA
1.4%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 85%